WuXi AppTec Participates In $5.9 Million Series A For Rodeo Therapeutics

Rodeo Therapeutics of Seattle announced a $5.9 million Series A financing put together by Accelerator Corporation with participation from investors that included WuXi AppTec. Rodeo is developing small-molecule therapies to promote tissue repair. It intends to develop drugs that treat inflammatory bowel disease and increase blood cell regeneration after a bone marrow transplant. The Accelerator Corporation, located in Seattle, provides Rodeo with a corporate home and shares its CEO, Thong Le, with Rodeo.

Back to news